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ABSTRACT
Introduction: IDegLira is a once-daily
combination of insulin degludec (IDeg) and
liraglutide. Trials directly comparing IDegLira
with alternative strategies for intensifying basal
insulin are ongoing. While awaiting results, this
analysis compared indirectly how different
strategies affected glycated hemoglobin
(HbA1c) and other outcomes.
Methods: A pooled analysis of five completed
Novo Nordisk randomized clinical trials in
patients with type 2 diabetes inadequately
controlled on basal insulin was used to
compare indirectly IDegLira (N = 199) with:
addition of liraglutide to basal insulin
(N = 225) [glucagon-like peptide-1 receptor
agonist (GLP-1RA) add-on strategy];
basal–bolus (BB) insulin [insulin glargine
(IGlar) ? insulin aspart] (N = 56); or
up-titration of IGlar (N = 329). A
supplementary analysis was performed with
the BB arm including patients who received
IGlar or IDeg as basal insulin in the relevant
trial (N = 210). All trials had comparable
inclusion/exclusion criteria and baseline
characteristics. Individual patient-level data
were analyzed using multivariable statistical
models with potential baseline heterogeneity
accounted for using explanatory variables.
Results: At end of study, differences between
IDegLira and BB or up-titrated IGlar, respectively,
were as follows: reduction in HbA1c-0.30%, 95%
confidence interval (–0.58; -0.01) and -0.65%
(-0.83; -0.47); change in body weight -6.89 kg
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(-7.92;-5.86) and-4.04 kg (-4.69;-3.40) all in
favor of IDegLira. Confirmed hypoglycemia rate
was 122.8 (90.7; 166.1), 1060.8 (680.2; 1654.4),
and 286.1 (231.1; 354.1) events/100
patient-years for IDegLira, BB, and up-titrated
IGlar, respectively. Odds ratios for achieving
HbA1c\7.0%,\7.0% without hypoglycemia,
and \7.0% without hypoglycemia and no
weight gain were greater with IDegLira versus
up-titrated IGlar. The supplementary analysis
yielded similar results to the main analysis.
Results with IDegLira were similar to those for
the ‘GLP-1RA add-on’ arm.
Conclusion: These results suggest that IDegLira
may be more effective, with lower
hypoglycemia rates and less weight gain, than
up-titrated basal insulin or BB in patients
uncontrolled on basal insulin.
Keywords: Basal insulin; IDegLira; Insulin
degludec; Intensification; Liraglutide; Type 2
diabetes
INTRODUCTION
When patients with type 2 diabetes do not
achieve glycemic control with basal insulin,
common strategies are to titrate the basal
insulin further, add bolus insulin, or switch to
premix insulin. These options improve
glycemic control but may increase rates of
hypoglycemia and weight gain. A more recent
option has been to add a glucagon-like
peptide-1 receptor agonist (GLP-1RA) to the
basal insulin [1, 2], which has potential
advantages. With their different modes of
action, basal insulin and GLP-1RAs target
several of the multiple pathophysiological
defects that contribute to type 2 diabetes.
By supplementing endogenous insulin
secretion, basal insulin may also facilitate
beta-cell rest and hence restore the prandial
insulin response to some degree [3, 4].
GLP-1RAs stimulate insulin secretion and
suppress glucagon secretion in a
glucose-dependent manner [5, 6], as well as
delaying gastric emptying and reducing
appetite [7]. Gastrointestinal adverse events
(AEs), in particular nausea, are associated with
GLP-1RAs [8]. GLP-1 itself increases satiety [9];
the GLP-1RA liraglutide has been shown to
exert the same effect [10], and to be associated
with weight loss [8].
Combining a basal insulin and a GLP-1RA
has the potential to yield improved clinical
results to those expected from either therapy
alone—providing better glycemic control
arising from reductions in both fasting plasma
glucose (FPG) and postprandial glucose, and less
associated hypoglycemia and less weight gain
compared with the use of basal insulin alone
[11]. This has indeed been the case; for example,
in the VICTOZA ADD-ON study
(NCT01388361), addition of the GLP-1RA
liraglutide to insulin degludec resulted in
greater reductions in glycated hemoglobin
(HbA1c) at 26 weeks relative to adding a single
daily dose of insulin aspart [12]. Weight loss and
lower rates of hypoglycemia were observed in
the liraglutide plus insulin degludec group.
Insulin degludec/liraglutide (IDegLira) is a
novel, once-daily combination of insulin
degludec and liraglutide in one pen device.
Insulin degludec is a once-daily basal insulin
with an ultra-long duration of action.
Liraglutide is a long-acting once-daily human
GLP-1 RA, for the treatment of adult patients
with type 2 diabetes. The distinct
pharmacological properties of each component
are maintained in the combination formulation
and after injection. IDegLira is administered as
dose steps, titrated to FPG target levels, with
each dose step comprising 1 U of insulin
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degludec and 0.036 mg of liraglutide. The
maximum daily single administration is 50
dose steps (50 U insulin degludec/1.8 mg
liraglutide). The combined formulation makes
it possible to titrate both insulin degludec and
liraglutide at a slow and steady rate. IDegLira
received marketing authorization from the
European Medicines Agency and Swissmedic
(the Swiss Agency for Therapeutic Products) in
September 2014.
Studies in the development program for
IDegLira are shown in Table S1. To date, two
phase 3a trials have been completed and fully
published: DUAL I [NCT01336023; IDegLira
versus insulin degludec and liraglutide in
insulin-naı¨ve patients uncontrolled on oral
antidiabetic drugs (OADs)], including an
extension trial [13, 14]; and DUAL II
(NCT01392573; IDegLira versus capped-dose
insulin degludec in patients uncontrolled on
basal insulin plus OADs) [15]. In DUAL I,
IDegLira was superior to liraglutide alone, and
non-inferior to insulin degludec, in reducing
mean HbA1c from baseline. Confirmed
hypoglycemia occurred less frequently with
IDegLira than with insulin degludec, but
significantly more frequently than with
liraglutide. Patients using IDegLira lost weight,
with lower weight loss versus liraglutide, while
patients treated with insulin degludec gained
weight [13].
DUAL II enrolled patients who had not
achieved control on basal insulin therapy [15].
In DUAL II, mean HbA1c reduction from
baseline was greater with IDegLira versus
capped-dose insulin degludec; the risk of
hypoglycemia was low and comparable to that
with insulin degludec; and patients lost weight
with IDegLira but not with insulin degludec
[15]. However, the insulin treatment arm had
the dose capped at 50 units, to meet regulatory
requirements and illustrate the potential
relative contribution of the liraglutide
component to the effect of IDegLira. While
this study illustrated the contribution of the
liraglutide component to the outcomes
achieved with IDegLira, the dose capping
meant it was not possible to compare the
clinical success of IDegLira with further
up-titration of basal insulin beyond 50 units.
For clinical practice, it is of interest to know
whether IDegLira is a useful alternative to other
strategies for intensification of basal insulin
therapy. Currently, however, data from
head-to-head trials of IDegLira versus
uncapped basal insulin (alone or in
combination with other drugs) in patients
inadequately controlled on basal insulin have
not yet been fully published. While further
evidence from the clinical trial program is
awaited, a provisional indirect estimate of the
relative treatment effects was obtained through
a pooled analysis based on patients who used
IDegLira in the DUAL II trial and patients using
basal insulin, alone or in combination with
bolus insulin or liraglutide, in four other Novo
Nordisk-sponsored trials with comparable
inclusion/exclusion criteria and baseline
characteristics. The methodology used in the
pooled analysis is supported by the European
Network for Health Technology Assessment
guidelines on how to conduct indirect
analyses [16], and has been used previously for
indirect comparisons in diabetes [17].
METHODS
Choice of Analysis and Source of Data
To evaluate the efficacy of IDegLira compared
with commonly used basal insulin
intensification strategies in a population
inadequately controlled on basal insulin, a
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pooled multivariable analysis using treatment
arms from different trials was applied. For these
analyses, we used individual patient-level data
available in the Novo Nordisk clinical trial
database, from trials that met specific criteria.
Trials were identified by conducting a search
using the ‘TrialTrove’ database of clinical trials
intelligence (search strategy is shown in
Figure S1). Briefly, to qualify, trials had to be
phase III or IV randomized controlled trials
(RCTs) that used IDegLira, insulin glargine
(IGlar), insulin detemir, or liraglutide as the
intervention drug. To eliminate bias in the
selection of patients, extension studies, or
studies that re-randomized patients from an
immediate preceding trial, did not qualify.
Studies had to have been conducted in the
target population, i.e., patients with type 2
diabetes already using a basal insulin but with
uncontrolled glycemia. Studies also had to
include a treatment arm that used either
IDegLira or a current standard of care for such
patients (see Figure S1 for details). These criteria
were applied to ensure similar patient
populations and similar trial designs.
Five trials (including DUAL II) that met all
these criteria were identified (Table 1) [15,
18–21]. In all the trials, insulin was titrated to
FPG targets similar to those used in DUAL II
[72–90 mg/dL (4.0–5.0 mmol/L)]. However, in
the LIRA-ADD2BASAL study (NCT01617434)
[18], the pre-trial insulin dose was reduced by
20% when patients entered the trial; this
mimics clinical practice, where the initiation
of liraglutide as add-on to basal insulin is
accompanied by a reduction in insulin dose.
Following randomization, insulin adjustments
above pre-trial dose were not allowed, as the
objective was to assess the effect of the added
liraglutide.
Trials of non-injectable add-on therapies to
basal insulin (such as pioglitazone, gliptins or
sodium–glucose co-transporter-2 inhibitors)
were not included in this analysis because the
Novo Nordisk clinical trial database did not
include any such trials that fulfilled the
selection criteria at the time of the analysis,
and therefore individual patient-level data were
not available.
All of the identified trials were controlled,
randomized, parallel-group trials, and were
either open-label or double-blind. In general,
only one treatment arm, or a subset of one
treatment arm, from each trial was used, as the
objective was to compare the efficacy of
IDegLira in DUAL II to other treatment
regimens. For basal–bolus therapy, initially
only patients treated with IGlar ? insulin
aspart were included in the pooled analysis,
but a supplementary analysis was also
performed that included patients treated with
insulin degludec ? insulin aspart as well (see
below). Neutral protamine Hagedorn was not
included as a comparator because it was not
used in any of the identified trials.
The use of treatment arms from different
trials raised the potential for systematic
differences in the patient populations. To
account for differences between the cohorts,
additional baseline characteristics as compared
to the models used in the original trials (listed
below under ‘‘Statistical Methods’’) were
included in the pooled statistical analyses.
This was possible because the analyses were
based on individual patient-level data.
Outcome Measures
The primary endpoint was change in HbA1c
from baseline to end of study. Secondary
endpoints were confirmed hypoglycemia (with
rates reported for overall, severe, and
non-severe episodes); change from baseline in
body weight and body mass index (BMI); and
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responder rate, i.e., percentage of patients
achieving an HbA1c level of \7.0%
(53 mmol/mol), as well as achievement of
HbA1c \7.0% without confirmed
hypoglycemia, and achievement of HbA1c
\7.0% without confirmed hypoglycemia and
no weight gain. Confirmed hypoglycemia was
defined as the occurrence of severe episodes
(i.e., requiring assistance), or episodes in which
plasma glucose concentration (confirmed by
self-monitored blood glucose) was less than
56 mg/dL (3.1 mmol/L), irrespective of
symptoms. A number of other endpoints were
also reported, including total insulin dose at
end of treatment, and change from baseline in
systolic blood pressure (SBP), total cholesterol,
low-density lipoprotein (LDL) cholesterol,
high-density lipoprotein (HDL) cholesterol,
and triglycerides.
Statistical Methods
When analyzing the results from a randomized
controlled trial, randomization accounts for
systematic bias, but subjects’ baseline values
may be accounted for using multivariable
statistical methods to estimate the endpoint
conditional on the pretreatment value, and
consequently increase statistical efficiency. In
the current analysis, the conventional statistical
models that were pre-specified for analysis of
data from the DUAL II trial were supplemented
by including a number of additional clinically
relevant baseline characteristics in an attempt
to account for systematic differences between
patients, as comparisons did not have the
protection from bias achieved through
randomization.
The explanatory variables used in the pooled
statistical analyses were region, previous
antidiabetic treatment, and baseline value of
the variable being analyzed (e.g., baseline value
of HbA1c for the analysis of change in HbA1c).
Baseline value was not included for the analyses
of dose because all patients were titrated
towards a similar FPG target; thus, baseline
dose would not have an impact on any of the
end-of-trial treatment effects. In addition, the
following variables were included to account for
potential systematic differences between trial
populations: sex, disease duration, baseline
HbA1c, and baseline BMI. The baseline HbA1c
and baseline BMI were included as explanatory
variables in analyses of all the endpoints, not
just analyses of HbA1c and BMI, respectively.
These additional explanatory variables were
identified on the basis that they are clinically
relevant variables, which have the potential to
exert an impact on the clinical outcomes of
interest in the pooled analysis.
Weight was not included as an explanatory
variable since weight is a component of BMI,
which is included as an explanatory variable.
Similarly, age and race were not included as
they are related to disease duration and
geographical region, respectively, which were
both included as explanatory variables. Baseline
dose was not included as an additional
explanatory variable since it was expected to
be related to many of the other explanatory
variables, e.g., duration of diabetes, BMI, and
HbA1c.
In this paper, we report the estimated
changes from baseline accounting for baseline
characteristics, as well as the observed changes
from baseline in the variables listed above. We
also performed a supplementary analysis. In the
primary analysis, the basal–bolus arm consisted
of 56 patients who were treated with IGlar plus
insulin aspart in the BEGIN Basal–Bolus (BB)
trial (NCT00972283). The supplementary
analysis included patients treated with either
IGlar or insulin degludec, plus insulin aspart, in
BEGIN BB; this brought the number of patients
578 Diabetes Ther (2015) 6:573–591
in the BB arm of the current analysis to 210
(Table 1).
Continuous endpoints were analyzed using a
generalized linear model with an identity link
and Gaussian error. Counts were analyzed with
a loge link function and negative binomial
error, and responder endpoints were analyzed
with a logit link and binomial error. The model
used treatment, region, sex, and previous
antidiabetic treatment at baseline as factors
and diabetes duration, baseline BMI, and
baseline HbA1c as continuous explanatory
variables. The analysis is based on results at
end of treatment and the model was not
adjusted for different treatment durations, as
effects seen at 26 weeks are generally
maintained. As in the original trial protocols,
missing values were imputed using last
observation carried forward for all analyses.
The statistical package used was SAS version
9.4 (SAS Institute Inc., Cary, NC, USA).
The methods used are summarized in Fig. 1
[15, 18–21].
Compliance with Ethics Guidelines
This analysis did not involve any new research
on human subjects. The original clinical trials
included in the analysis were conducted in
accordance with Good Clinical Practice [22]. All
study procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013 [23]. Informed consent was obtained
from all patients for being included in the
study.
Fig. 1 Summary of method: pooled indirect analysis of
IDegLira OD versus other insulin intensiﬁcation strategies
in patients uncontrolled on basal insulin [15, 18–21].
ANCOVA analysis of covariance, BMI body mass index,
DPP-4 dipeptidyl peptidase-4 inhibitor, HbA1c glycated
hemoglobin, HDL high-density lipoprotein, IAsp insulin
aspart, IDeg insulin degludec, IDegLira insulin degludec/
liraglutide, IDet insulin detemir, IGlar insulin glargine,
LDL low-density lipoprotein, lira liraglutide, met met-
formin, OAD oral antidiabetic drug, OD once daily, pio
pioglitazone, SBP systolic blood pressure, SU sulfonylurea,
TID three-times daily
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RESULTS
As the inclusion criteria were comparable
across the five clinical trials, the treatment
arms were well matched with respect to
baseline characteristics (Table 2). However,
some differences in clinically relevant
parameters at baseline were observed. Mean
HbA1c level was higher, and mean disease
duration lower, for patients treated with
IDegLira (in the DUAL II trial) compared with
patients from the other trials. The difference in
HbA1c could be expected because the inclusion
criteria for DUAL II specified a minimum
HbA1c value of 7.5% (58 mmol/mol), whereas
for all other trials the minimum value was
7.0% (53 mmol/mol).
Efficacy Outcomes
The estimated reduction in HbA1c was
significantly greater with IDegLira (-1.68%;
95% confidence interval [-1.82; -1.54]) than
with GLP-1RA add-on to basal insulin (-1.33%
[-1.48; -1.18]), basal–bolus therapy (-1.39%
[-1.64; -1.13]), and up-titrated IGlar (-1.03
[-1.14; -0.93]) (Table 3a); estimated differences
are shown in Table 3b. For the remaining
parameters, estimated outcomes did not differ
significantly between IDegLira and the GLP-1RA
add-on to basal insulin arm (Table 3a, b).
Compared with BB or up-titrated basal
therapy, estimated improvements in body
weight, BMI, and SBP were statistically
significantly better with IDegLira. For example,
the estimated change in body weight was
-2.88 kg [-3.39; -2.37] with IDegLira,
?4.01 kg [?3.10; ?4.93] with basal–bolus, and
?1.16 kg [0.78; ?1.55] with up-titrated IGlar
(Table 3a).
A lower estimated insulin dose [37.8 units
(33.8; 41.8)] was required with IDegLira versus
BB [62.4 units (55.2; 69.7)] or up-titrated basal
therapy [60.7 units (57.6; 63.7)] (Table 3a, b).
Compared with GLP-1RA add-on, IDegLira
required a similar dose of basal insulin, but a
lower dose of GLP-1 RA (Table 3a).
The supplementary analysis (Table S2a and
b), with an increased number of subjects in the
BB arm, yielded very similar results to the main
analysis.
As expected, estimated changes from
baseline were slightly different from the
observed changes (Table S3) because the
estimated changes were adjusted for
differences in the patients’ baseline
characteristics. Observed changes and
estimated changes followed the same pattern
and magnitude for all parameters.
Hypoglycemia
Estimated rates of hypoglycemia are shown in
Table 4a and observed rates in Table S3; rate
ratios (IDegLira relative to alternative regimen)
and P values are shown in Table 4b. Estimated
rates of overall hypoglycemia and non-severe
hypoglycemia were significantly lower with
IDegLira with BB or up-titrated basal insulin
therapy (P\0.0001) (Table 4b). Rates of severe
hypoglycemia were too low for differences to
allow for meaningful statistical comparison.
Rates of overall hypoglycemia did not differ
between IDegLira [123 events/100 patient-years
of exposure (PYE) (91; 166)] and the GLP-1RA
add-on to basal insulin arm [124 events/100 PYE
(89; 173)].
The supplementary analysis (Table S4a, b)
yielded similar results to the main analysis.
Responder Rates
Estimated responder rates and odds ratios (ORs)
for these rates, for IDegLira versus comparators,
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are shown in Table 5a, b. The estimated
percentage of patients achieving HbA1c \7.0%
(53 mmol/mol) was 64.7% (IDegLira), 47.1%
(GLP-1RA add-on to basal insulin), 52.8% (BB),
and 31.9% (up-titrated IGlar) (Table 5a). The
estimated ORs for achieving HbA1c\7.0% were
significantly higher with IDegLira versus
GLP-1RA add-on to basal insulin [OR, 2.06
(1.28; 3.31)] and versus up-titrated IGlar [OR,
3.91 (2.58; 5.93)]. The estimated ORs for
achieving HbA1c \7.0% without hypoglycemia
were significantly greater with IDegLira versus BB
or up-titrated IGlar, and ORs for achieving HbA1c
\7.0% without hypoglycemia and no weight
gain were significantly greater with IDegLira
versus up-titrated IGlar (no subjects in the BB
group achieved this response) (Table 5a, b).
In the supplementary analyses, estimated
ORs in all three response categories were
significantly greater with IDegLira versus
up-titrated IGlar, similar to the main analysis.
In addition, with the use of a larger BB group,
estimated ORs in all three response categories
were significantly greater with IDegLira versus
BB (Table S5a, b).
DISCUSSION
At the time of writing, fully published results
of randomized trials comparing IDegLira with
other current standard-of-care options for
patients who have not achieved glycemic
control with basal insulin are not available.
However, indirect comparisons provide
information that could aid physicians and
health policy makers in their decision-making
process while awaiting results of direct
comparisons. We therefore used an indirect
method—a multivariable comparison, using
individual patient-level data from similarly
designed trials in the Novo Nordisk clinical
trial database—to obtain estimates of the
efficacy of IDegLira versus alternative
strategies for intensification of basal insulin.
The results of these analyses showed a
consistent pattern of efficacy for IDegLira,
with results that were generally significantly
better than those obtained with BB or
up-titrated basal insulin therapy. Results were
generally similar to those obtained by adding a
GLP-1RA to basal insulin, and were achieved
with a similar dose of basal insulin but lower
dose of liraglutide with IDegLira versus
liraglutide added to basal insulin.
Up-titrated basal insulin therapy was
included as a comparator arm because this
approach is often used in clinical practice with
patients who have failed to achieve glycemic
control on their current basal insulin regimen.
The superior glycemic control with IDegLira
versus basal insulin therapy may be ascribed to
the different effects of the individual
components, with insulin degludec primarily
responsible for the sustained lowering of FPG,
and liraglutide reducing postprandial plasma
glucose after all meals in addition to its effect in
reducing FPG [24]. Improved glycemic control
is achieved with lower constituent doses of
liraglutide and insulin degludec than would be
required for equivalent benefits using one or the
other treatment independently, as was seen in
the DUAL I trial [13].
Two effects may have contributed to the
reduction in body weight seen with IDegLira
and with GLP-1RA add-on to basal insulin. First,
treatment with liraglutide results in weight loss
[25]. Second, basal insulin is normally
associated with weight gain, and this was
indeed seen in the BB and basal-only
treatment arms, where insulin could be fully
titrated and end-of-trial doses of insulin were
higher than in the two treatment arms that
combined basal insulin with liraglutide.
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Changes in markers of cardiovascular risk
other than weight/BMI were included in these
analyses because previous studies have reported
improved SBP [25, 26] and blood lipid profiles
with liraglutide [27, 28], and it was anticipated
that a therapy including liraglutide may provide
superior results versus therapies that do not.
Results were generally improved with IDegLira
versus BB or up-titrated basal insulin therapy for
SBP, total cholesterol, and LDL cholesterol. For
these outcomes, results in the GLP-1RA add-on
to basal insulin group were similar to those seen
with IDegLira. Patterns of change in HDL and
triglycerides did not differ systematically
between treatment arms.
Rates of hypoglycemia were significantly
lower with IDegLira versus BB or up-titrated
basal insulin therapy, despite a mean reduction
in HbA1c that was significantly greater with
IDegLira. This result was expected because the
liraglutide component of IDegLira stimulates
insulin secretion and suppresses glucagon
secretion in a glucose-dependent manner [5,
24]. Furthermore, the use of a GLP-1RA results
in a lower dose of insulin being required, as was
seen in these analyses, which may further
decrease the risk of hypoglycemia.
Results for IDegLira and the GLP-1RA add-on
to basal insulin arm were, as expected, similar
except for reduction in HbA1c. For some
parameters (change in body weight, BMI, total
cholesterol, LDL), numerically greater
improvements were seen in the GLP-1RA
add-on to basal insulin arm than with
IDegLira. These differences might be explained
by the fact that individual titration of IDegLira
resulted in lower doses of liraglutide compared
to the GLP-1RA add-on to basal insulin arm,
and also the design of the GLP-1RA add-on trial,
in which insulin adjustments above pre-trial
dose were not allowed post-randomization,
since the objective was to assess the effect of
the added liraglutide [18].
A potential advantage of IDegLira versus
GLP-1RA add-on to basal insulin, not assessed
here, is the greater convenience that a single
once-daily injection offers patients. Also, the
slower titration of liraglutide in the IDegLira
arm, which follows the titration schedule for
the basal insulin component, is expected to give
rise to less nausea compared with independent
titration of liraglutide [13].
Responder rates for patients achieving a target
HbA1c of 7.0% (53 mmol/mol), and composite
response rates that included achievement of
HbA1c target together with no hypoglycemia or
no hypoglycemia and no weight gain, were
greater with IDegLira versus up-titrated basal
insulin therapy and versus BB therapy. Side
effects of therapy such as hypoglycemia and
weight gain may be of substantial concern to
patients and can be barriers to achieving good
HbA1c control from both patients’ and
physicians’ perspectives [29–32], and
hypoglycemia in particular has cost
implications for healthcare services [33].
Composite endpoints such as the ones used
here are therefore useful indicators of overall
treatment success. Furthermore, outcome
studies such as Action to Control
Cardiovascular Risk in Diabetes
(NCT00000620), Outcome Reduction With
Initial Glargine Intervention (NCT00069784),
and STENO-2 (NCT00320008) have suggested
that reduction in HbA1c, while important,
accounts only in part for overall treatment
success; factors such as rates of hypoglycemia
and changes in body weight may also contribute
to overall morbidity and mortality [34–36].
Safety was not specifically considered in this
analysis, apart from hypoglycemia. In the trials
used for the analysis [18–21], AEs typical of
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basal insulin and/or GLP-1RA therapy were
noted, with no major or unexpected patterns
or concerns arising. In DUAL II, the incidence of
gastrointestinal AEs was low, but slightly higher
for IDegLira versus insulin degludec [15].
The key limitation of this study was the need
to use an indirect comparison methodology.
RCTs are correctly the gold standard for
comparing treatments, as differences in
observed results within a randomized trial may
be ascribed to either chance or the randomized
treatment, providing unbiased estimates of
treatment effect. When results from RCTs are
not available, it is increasingly common to use
indirect comparisons. The multivariable model,
which accounts for individual patient
characteristics at baseline and was used here,
may be considered a superior approach to those
methods used when individual patient-level
data are not available [16]. The standard
multivariable method is a common approach
used in clinical trials to account for differences
in baseline characteristics to improve statistical
efficiency [37]. Propensity score methods were
explored initially to investigate differences
between IDegLira and basal-only, and IDegLira
and BB treatment. The conclusions based on the
propensity scores were in line with the results
presented here.
Our estimated data differed somewhat from
the observed data, as would be expected when
made conditional on baseline characteristics
that differed systematically between treatment
exposures. Our supplementary analyses, in
which the entire model was re-analyzed using
a larger BB patient group, is reassuring as it
yielded near-identical results to the main
analysis on key criteria; results differed for
some of the lipid values, which varied highly
between patients in all the different arms.
The clinical trial program for IDegLira will
provide direct comparisons between IDegLira
and other insulin intensification options. Since
the present analysis was performed, DUAL V
(NCT01952145), comparing IDegLira with
up-titrated IGlar, has been published in
abstract form [38]. The results of that
randomized comparison are in line with those
described here.
A comparison of IDegLira versus full BB
therapy is also included in the current clinical
development program. The results presented
here can therefore be considered interim results,
which may help guide clinical decisions,
bearing in mind that they are open to
systematic bias, until the randomized
comparisons are available.
CONCLUSION
In this indirect analysis of injectable insulin
intensification strategies, results with IDegLira
were similar or significantly better than those
obtained with BB therapy, up-titrated basal
insulin therapy, or liraglutide added to basal
insulin. Until direct comparisons are available,
these indirect results show that IDegLira may
offer a useful treatment alternative for patients
with type 2 diabetes who have failed to achieve
glycemic control using basal insulin therapy.
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